Ann Dermatol.  2018 Aug;30(4):485-488. 10.5021/ad.2018.30.4.485.

Differential Effects of Digoxin on Imiquimod-Induced Psoriasis-Like Skin Inflammation on the Ear and Back

• Madsen M
• Pedersen T
• Nielsen LB
• Johansen C
• Hansen PR

• KMID: 2457533
• DOI: http://doi.org/10.5021/ad.2018.30.4.485

Abstract

No abstract available.

MeSH Terms

Digoxin*
Ear*
Inflammation*
Skin*
Digoxin

Figure

• 

  Fig. 1 Differential effects of digoxin on imiquimod (IMQ)-induced psoriasis-like skin inflammation on the ear and back. IMQ-induced skin thickening was assessed in the ear (A, B) and in the back skin (C, D). Thicknesses of the ear (A) and the back skin fold (C; left panel) were measured daily with a micrometer, from day 1 or 3 (A and C, respectively) until day 6. The back skin was visually scored for erythema and scaling each on a scale from 0~4 and the sum score (0–8) is presented (C; right panel). Values are presented as mean±standard deviation. Mean numbers of epidermal cell layers in the ear (B) and back skin (D) were assessed in H&E stained sections. Representative photos are also displayed (scale bar: 50 µm). Statistics were performed using two-way ANOVA with Tukey's correction for multiple comparisons. Due to technical difficulties, data from one mouse are missing from the vehicle cream (Veh)-control group (B) and from the Veh-digoxin group (D), respectively.

Reference

1. Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013; 133:17–26.

2. van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009; 182:5836–5845.

3. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006; 126:1121–1133.

4. Banerjee D, Zhao L, Wu L, Palanichamy A, Ergun A, Peng L, et al. Small molecule mediated inhibition of RORγ-dependent gene expression and autoimmune disease pathology in vivo. Immunology. 2016; 147:399–413.

5. Pantelyushin S, Haak S, Ingold B, Kulig P, Heppner FL, Navarini AA, et al. Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice. J Clin Invest. 2012; 122:2252–2256.

6. Skepner J, Ramesh R, Trocha M, Schmidt D, Baloglu E, Lobera M, et al. Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo. J Immunol. 2014; 192:2564–2575.

7. Huh JR, Leung MW, Huang P, Ryan DA, Krout MR, Malapaka RR, et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity. Nature. 2011; 472:486–490.

8. Shi H, Mao X, Zhong Y, Liu Y, Zhao X, Yu K, et al. Digoxin reduces atherosclerosis in apolipoprotein E-deficient mice. Br J Pharmacol. 2016; 173:1517–1528.

9. Schaper K, Dickhaut J, Japtok L, Kietzmann M, Mischke R, Kleuser B, et al. Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis. J Dermatol Sci. 2013; 71:29–36.

10. Grine L, Steeland S, Van Ryckeghem S, Ballegeer M, Lienenklaus S, Weiss S, et al. Topical imiquimod yields systemic effects due to unintended oral uptake. Sci Rep. 2016; 6:20134.